Trial Profile
Optical Coherence Tomography for EVERolimus Eluting STent (OCTEVEREST).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms OCTEVEREST
- 14 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 31 Jul 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Jun 2010).
- 21 Jun 2010 New trial record